WO2002043756A2 - Método de obtención de agregados antigénicos y su uso en formulaciones - Google Patents
Método de obtención de agregados antigénicos y su uso en formulaciones Download PDFInfo
- Publication number
- WO2002043756A2 WO2002043756A2 PCT/CU2001/000009 CU0100009W WO0243756A2 WO 2002043756 A2 WO2002043756 A2 WO 2002043756A2 CU 0100009 W CU0100009 W CU 0100009W WO 0243756 A2 WO0243756 A2 WO 0243756A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigens
- antigenic
- hbsag
- aggregate
- structures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention is related to the branch of medicine, particularly with the use of new vaccine formulations.
- the technical objective pursued with the proposed invention is the development of a method of obtaining aggregate antigenic structures and their formulations, capable of enhancing the immunogenicity of the antigens contained from the systemic and / or mucosal immunization thereof.
- the method described in the present invention generates antigenic structures of aggregate nature of particulate antigens, the addition of other antigens, compounds with aggregating, delipidating or oxidizing characteristics, the subsequent selection of aggregate particles between 30 and 500 nm in size, and the formulation of said suitably adjuvant aggregates favor the immunogenicity of the resulting antigenic composition.
- HBsAg is an efficient immunogen, it became the first vaccine candidate widely used in humans and the first recombinant hepatitis B vaccine licensed for universal use.
- HBsAg proteins self-assemble into 22 nm particles (Heerman KH, Gerlich WH,
- MHC apparently operates alternative processes for CD4 + T cells restricted to MHC class II and for CD8 + T cells restricted to MHC class I (Germain, RN. Et al. 1993. Annu Rev Immun ⁇ l. 11: 403).
- a new endosomal pathway for the processing of exogenous HBsAg particles has been described for the presentation of MHC class I-restricted epitopes.
- This exogenous heat denatured and 1 ⁇ m diameter HBsAg processing occurs in macrophages, but not in others. cell types and is accompanied by regurgitation of antigenic peptides from the macrophage processor.
- This process of generating exogenous antigen peptides for presentation restricted to MHC class I has been tentatively designated as the phagocytic pathway.
- the native 22 nm HBsAg particles are processed primarily by endocytic route and 1 ⁇ m aggregates by phagocytic route.
- their in vivo immunogenicity for CTL class I was markedly different when shipped without adjuvants.
- the native HBsAg particle was of high immunogenicity while denatured aggregates of the surface antigen were of low immunogenicity (Schirmbeck, R. et al. 1995. J Immunol 155: 4676-4684).
- Other studies using fluorescence polarization suggest that the HBsAg particle is organized as a lipid bilayer that interacts with protein aggregates (Sonveaux N.
- One of the objects of the present invention is a method of obtaining aggregate antigenic structures of greater immunogenicity than the antigens that gave rise to them.
- Said method comprises the following steps: A) Selection of the antigens of interest; B) Addition of one or more antigens of the mixture in a medium that favors the aggregation process, said medium may consist of chemical agents, oxidizing agents or other components with aggregating capacity
- aggregates containing only the surface antigen of the HBV can be obtained, also to combinations of the surface antigen and other homologous or heterologous, lipoproteic, lipopeptide or lipidic antigens of any viral, bacterial, unicellular pathogen or multicellular.
- the antigens that are part of the structures obtained in step (B) can be added to the hepatitis B virus surface antigen by hydrophobic, electrostatic or covalent interactions, generating aggregates of various sizes.
- the method of obtaining antigenic structures allows the aggregation of the nucleocapsid antigen of the Hepatitis B, C, or HIV virus and the surface antigen of the Hepatitis B Virus, antigens from viruses and bacteria such as viruses can also be added inactivated and outer membrane proteins of bacterial pathogens such as Neisseria meningitidis.
- ⁇ -cyclodextrins can be used as a chemical agent that favors delipidation, membrane association and aggregation between the particles present, other chemical agents are ammonium salts at concentrations between 10 and 50 mM, enhanced by metal salts of copper and iron, or others that allow aggregation.
- Other elements of the method that have spontaneous aggregating activity which can be used together or alone for this purpose are homologous or heterologous antigens that evidenced aggregating activity on HBsAg, including viral nucleocapsid antigens and also derived from external membranes of bacteria or viral covers of a lipoprotein or hydrophobic nature.
- the method of the present invention allows the aggregation of HBsAg or HBsAg with other antigens or adjuvants from the development of hydrophobic interactions, electrostatic or covalent bonds, in incubation periods in a range of between 10 minutes and one week depending of the selected constituents.
- the separation of the aggregates is carried out by a screening method according to molecular size, among them the method of molecular exclusion chromatography, dialysis, diafiltration or other method that allows the retention of molecular sizes between 30 and 500 nm
- a screening method according to molecular size among them the method of molecular exclusion chromatography, dialysis, diafiltration or other method that allows the retention of molecular sizes between 30 and 500 nm
- the method of the present invention provides for the adjuvant of the resulting structures to adjuvants such as aluminum salts, calcium, Oils, or other commercially used adjuvant, other antigens, stabilizers and preservatives may also be added to the final formulation.
- adjuvants such as aluminum salts, calcium, Oils, or other commercially used adjuvant, other antigens, stabilizers and preservatives may also be added to the final formulation.
- Another object of the present invention is the aggregate antigenic structure obtained according to the method described above, which favors an increase in the immunogenicity of the resulting formulation and a differential recognition by the immune system of the epitopes involved.
- Said aggregate antigenic structures are characterized in that they contain the surface antigen of the Hepatitis B Virus, alone or in combination with other antigens forming the aggregate.
- These other antigens are lipoprotein or hydrophobic, including HBcAg, and also have the intrinsic property of favoring the aggregate state between them by hydrophobic junctions.
- Other viral capsid and lipoprotein or hydrophobic nature antigens have been shown to possess this ability, including the nucleocapsid antigens of the Virus of the
- the antigenic structures object of the present invention are associations of HBsAg with adjuvants of hydrophobic nature which can be part of the aggregate by the same method previously described.
- the antigenic structures object of the present invention can be obtained from the aggregation by the above-described method of one, two or more particles of hydrophobic nature and at least one of particulate nature and are visible by electron microscopy as described in the examples. The aggregation of these structures favors immunological modulation, differential recognition and increased immunogenicity in general.
- the antigenic structures object of the present invention it is possible to use them for the rational design of human and veterinary vaccines, both preventive and therapeutic, through systemic and mucosal routes and their use in diagnostic systems .
- the advantages of the new preparations resulting from the use of the method of obtaining this type of antigens are: the increase in immunogenicity, the possibility of overlapping of new adjuvants, immunomodulators and antigens during aggregation.
- the preparations resulting from the method object of this invention may, depending on the route of inoculation and the species to be immunized, volumes from 0.01 to 10 mL and the dose of antigen may vary between 0.001 to 1 mg in the final vaccine formulation.
- Example 1 Obtaining vaccine formulations of surface antigen aggregates of the Hepatitis B Virus obtained with the use of cyclodextrins.
- the particles were obtained from the native 22 nm antigen by controlled treatment of the antigen with chemical compounds of the lipid-subtracting activity of the particle, in this case the cyclodextrins were used at concentrations greater than 1 mg / mL and, depending on the concentration thereof incubation time varied, from 24 hours to 7 days.
- the incubation temperature used in this test was 28 ° C although we have seen that at higher and lower temperatures, it is possible to obtain the aggregates. Temperature is a factor that favored the process of partial delipidation through oxidation and lipid subtraction.
- the different aggregates were analyzed by gel filtration and electron microscopy, with sizes ranging from tens of nanometers to particles that precipitated by their size.
- the antigen was selected depending on its size for immunochemical analyzes. These analyzes demonstrated a decrease in the level of lipids with respect to the level of proteins. It has been demonstrated by HPLC that these aggregates have a high stability over time.
- the added antigen was adsorbed to alumina at a final concentration between 0.002 mg / mL and 0.1 mg / mL and was used in immunogenicity tests.
- a variant of incubation with cyclodextrins at different times and temperatures involved the addition to the sample of immunomodulatory compounds such as lipopolysaccharides and saponins, which formed part of the final aggregate that was adsorbed to alumina to form the final vaccine formulation.
- Example 2 Obtaining vaccine formulations of surface antigen aggregates of the Hepatitis B Virus using oxidizing agents.
- Example 3 Obtaining vaccine formulations of chemical overparticulate structures, obtained by modifying the incubation conditions of the yeast.
- the particles were obtained naturally from the yeast Picchia pastor ⁇ s, the antigen was selected during the purification process due to its physicochemical characteristics.
- the antigen production process is subjected to long culture times, exceeding 100 hours, and oxidative stress conditions. This process allows a part of the antigen to remain in its native state of 22 nm but an important part, by increasing the intracellular oxidation conditions, is added and delipidated, as was demonstrated by lipid analysis and proteins made to the samples of the different peaks obtained in the gel filtration.
- the fraction is subsequently separated by HPLC gel filtration on TSK G5000 columns. This material constitutes 10% of the entire antigen, and is currently discarded. Adjuvation occurs by adsorption to alumina under similar conditions to those of the normal antigen.
- the analysis of both antigens showed that HBsAg is added in a process in which a significant amount of lipids of all types is lost, in the table below the phospholipids of both antigens are analyzed.
- mice Female Balb / c mice from 10 to 15 weeks of age were immunized by intranasal and intramuscular routes. The doses per mouse are presented in the table at the end of the example and the results in Figure 1A, Figure 1 B presents a sample of the HBsAg aggregates. The statistical analysis of the results was performed by the Student test: p ⁇ 0.05 was considered a significant difference.
- the antigens of groups 5 and 6, 7 and 8 and 9 and 10 were obtained by incubating at different times and concentrations of cyclodextrin obtaining different degrees of aggregation.
- Example 6 Evaluation of the lgG1 / lgG2a ratio.
- the lgG1 / 2a ratio for the normal HBsAg group immunized with alumina was 6.2 times higher than that found for the intermediate size delipidated HBsAg group. From this experiment it could be concluded that the different presentation of the surface antigen not only generates a quantitative but qualitative change, due to the type of IgG that is enhanced and due to the correlation of these variations in the IgG subclass pattern with increases in the response cellular, which corroborates the findings in the evaluation of the DTH response.
- Example 7 Study of the anti-HBsAg reactivity native to sera from mice immunized with different antigenic variants. After immunization of mice with the delipidated antigens obtained according to examples 1, 2 and 3, the reactivity of these sera was compared with the sera of mice immunized with the normal antigen. As a result of this experiment it was observed that the immune response generated by sera from mice immunized with the different variants had a different reactivity against normal HBsAg (22 nm), the highest reactivity was the sera of mice immunized with normal antigen, while , at different degrees of delipidation, reactivity against HBsAg varied.
- Example 8 Recognition of linear epitopes of sera of antigens immunized with different variants.
- a cellulose membrane mapping containing the linear sequences of the HBsAg (S region) was performed. 37 peptides of 12 overlapping 12 amino acids each were synthesized in 6 until the protein sequence was completed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01998363A EP1346727B1 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining delipidated hepatitis b antigenic aggregates and their use thereof |
AT01998363T ATE465752T1 (de) | 2000-12-01 | 2001-11-29 | Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung |
AU2002221518A AU2002221518B2 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
AU2151802A AU2151802A (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
JP2002545726A JP4974441B2 (ja) | 2000-12-01 | 2001-11-29 | 抗原性凝集物を得る方法と製剤におけるその使用 |
BR0115859-7 BRPI0115859B8 (pt) | 2000-12-01 | 2001-11-29 | método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina |
US10/433,492 US20040202676A1 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
DE60141978T DE60141978D1 (de) | 2000-12-01 | 2001-11-29 | Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung |
KR1020037007094A KR100873675B1 (ko) | 2000-12-01 | 2001-11-29 | 항원응집체의 수득방법 및 제제에서의 이의 용도 |
CA2429543A CA2429543C (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
US11/870,088 US20090104223A1 (en) | 2000-12-01 | 2007-10-10 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20000279A CU23002A1 (es) | 2000-12-01 | 2000-12-01 | Método de obtención de agregados antigénicos y su uso en formulaciones |
CU2000-0279 | 2000-12-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/870,088 Division US20090104223A1 (en) | 2000-12-01 | 2007-10-10 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002043756A2 true WO2002043756A2 (es) | 2002-06-06 |
WO2002043756A3 WO2002043756A3 (es) | 2003-01-09 |
Family
ID=5459569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2001/000009 WO2002043756A2 (es) | 2000-12-01 | 2001-11-29 | Método de obtención de agregados antigénicos y su uso en formulaciones |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040202676A1 (es) |
EP (1) | EP1346727B1 (es) |
JP (1) | JP4974441B2 (es) |
KR (1) | KR100873675B1 (es) |
CN (1) | CN1253206C (es) |
AR (1) | AR031437A1 (es) |
AT (1) | ATE465752T1 (es) |
AU (2) | AU2002221518B2 (es) |
BR (1) | BRPI0115859B8 (es) |
CA (1) | CA2429543C (es) |
CU (1) | CU23002A1 (es) |
DE (1) | DE60141978D1 (es) |
ES (1) | ES2342150T3 (es) |
PT (1) | PT1346727E (es) |
RU (1) | RU2266754C2 (es) |
WO (1) | WO2002043756A2 (es) |
ZA (1) | ZA200303948B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037311A1 (es) * | 2003-10-20 | 2005-04-28 | Centro De Ingenieria Genetica Y Biotecnologia | Composiciones farmacéuticas para uso terapéutico |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1802746T3 (pl) * | 2004-10-27 | 2011-10-31 | Crucell Switzerland Ag | Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B |
EP1652914A1 (en) * | 2004-10-27 | 2006-05-03 | Berna Biotech AG | Virosome particles comprising antigens from influenza virus and Hepatitis B virus |
CA2616344C (en) * | 2005-07-27 | 2010-10-12 | Lipid Sciences, Inc. | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
AR107262A1 (es) | 2016-01-27 | 2018-04-11 | Lilly Co Eli | Inactivación de patógenos por delipidación |
ES2965709T3 (es) | 2016-03-31 | 2024-04-16 | Ct Ingenieria Genetica Biotecnologia | Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0174759A1 (en) * | 1984-08-22 | 1986-03-19 | Connaught Laboratories Limited | Multispecific immunogenic proteins |
EP0231039A1 (en) * | 1986-01-14 | 1987-08-05 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728804A (en) * | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
AU2001266163B2 (en) * | 2000-06-22 | 2006-07-13 | Celltech Pharmaceticals Limited | Modification of hepatitis b core antigen |
US8092734B2 (en) * | 2004-05-13 | 2012-01-10 | Aptina Imaging Corporation | Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers |
-
2000
- 2000-12-01 CU CU20000279A patent/CU23002A1/es unknown
-
2001
- 2001-11-29 DE DE60141978T patent/DE60141978D1/de not_active Expired - Lifetime
- 2001-11-29 CN CNB018198236A patent/CN1253206C/zh not_active Expired - Lifetime
- 2001-11-29 AU AU2002221518A patent/AU2002221518B2/en not_active Ceased
- 2001-11-29 WO PCT/CU2001/000009 patent/WO2002043756A2/es active Application Filing
- 2001-11-29 US US10/433,492 patent/US20040202676A1/en not_active Abandoned
- 2001-11-29 KR KR1020037007094A patent/KR100873675B1/ko active IP Right Grant
- 2001-11-29 CA CA2429543A patent/CA2429543C/en not_active Expired - Fee Related
- 2001-11-29 AU AU2151802A patent/AU2151802A/xx active Pending
- 2001-11-29 AT AT01998363T patent/ATE465752T1/de active
- 2001-11-29 EP EP01998363A patent/EP1346727B1/en not_active Expired - Lifetime
- 2001-11-29 BR BR0115859-7 patent/BRPI0115859B8/pt not_active IP Right Cessation
- 2001-11-29 JP JP2002545726A patent/JP4974441B2/ja not_active Expired - Lifetime
- 2001-11-29 PT PT01998363T patent/PT1346727E/pt unknown
- 2001-11-29 RU RU2003119455/13A patent/RU2266754C2/ru active
- 2001-11-29 AR ARP010105554A patent/AR031437A1/es not_active Application Discontinuation
- 2001-11-29 ES ES01998363T patent/ES2342150T3/es not_active Expired - Lifetime
-
2003
- 2003-05-21 ZA ZA200303948A patent/ZA200303948B/en unknown
-
2007
- 2007-10-10 US US11/870,088 patent/US20090104223A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0174759A1 (en) * | 1984-08-22 | 1986-03-19 | Connaught Laboratories Limited | Multispecific immunogenic proteins |
EP0231039A1 (en) * | 1986-01-14 | 1987-08-05 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
Non-Patent Citations (2)
Title |
---|
BABAEVA E E ET AL: "ANTIGENIC DETERMINANTS OF NORMAL SERUM PROTEINS ASSOCIATED WITH HEPATITIS B VIRUS HEPATITIS B SURFACE ANTIGEN" VOPROSY VIRUSOLOGII, num. 4, 1981, páginas 442-446, XP002209718 ISSN: 0507-4088 * |
See also references of EP1346727A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037311A1 (es) * | 2003-10-20 | 2005-04-28 | Centro De Ingenieria Genetica Y Biotecnologia | Composiciones farmacéuticas para uso terapéutico |
Also Published As
Publication number | Publication date |
---|---|
RU2266754C2 (ru) | 2005-12-27 |
ZA200303948B (en) | 2004-03-30 |
EP1346727A2 (en) | 2003-09-24 |
ES2342150T3 (es) | 2010-07-02 |
KR100873675B1 (ko) | 2008-12-11 |
AR031437A1 (es) | 2003-09-24 |
US20040202676A1 (en) | 2004-10-14 |
CN1477972A (zh) | 2004-02-25 |
AU2151802A (en) | 2002-06-11 |
WO2002043756A3 (es) | 2003-01-09 |
KR20030068161A (ko) | 2003-08-19 |
EP1346727B1 (en) | 2010-04-28 |
BRPI0115859B1 (pt) | 2020-10-13 |
CN1253206C (zh) | 2006-04-26 |
DE60141978D1 (de) | 2010-06-10 |
ATE465752T1 (de) | 2010-05-15 |
PT1346727E (pt) | 2010-05-21 |
CA2429543A1 (en) | 2003-05-20 |
US20090104223A1 (en) | 2009-04-23 |
BR0115859A (pt) | 2003-12-30 |
CU23002A1 (es) | 2004-11-18 |
BRPI0115859B8 (pt) | 2021-05-25 |
JP2004529861A (ja) | 2004-09-30 |
AU2002221518B2 (en) | 2006-06-01 |
JP4974441B2 (ja) | 2012-07-11 |
CA2429543C (en) | 2012-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2285036T3 (es) | Coadyuvantes basados en una emulsion y mpl para vacunas. | |
JP3901731B2 (ja) | サポニンおよびステロールを含有するワクチン | |
CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
JP5559847B2 (ja) | ワクチンに使用するためのhbv抗原の精製 | |
Skrastina et al. | Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles | |
JP4685005B2 (ja) | アジュバントを含む機能的に再構成されたウイルス膜 | |
US20090104223A1 (en) | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations | |
Tiwari et al. | Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen | |
JP4870085B2 (ja) | 新たなクラスのウイロソーム粒子 | |
ES2264273T3 (es) | Preparaciones que contienen particulas similares a virus como inmunopotenciadores administrados a traves de mucosas. | |
ES2242376T3 (es) | Administracion de particulas inmunogenas mediante particulas de agshb. | |
WO2011038701A1 (es) | Formulación de antigenos del virus de la hepatitis b para la estimulación celular seguida de la inmunización terapéutica | |
CN109219449B (zh) | 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 | |
Garçon et al. | Liposomes to Induce Potent Humorale Responses to T-Independent Antigens | |
Glück | Immunopotentiating reconstituted influenza virosomes (IRIVs) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 770/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429543 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/03948 Country of ref document: ZA Ref document number: 200303948 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002221518 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037007094 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018198236 Country of ref document: CN Ref document number: 2002545726 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001998363 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: RU Ref document number: RU A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037007094 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001998363 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433492 Country of ref document: US |